Evolus posts scientific investor presentation on Jeuveau, Evolysse HA fillers, Profhilo skin-quality injectable portfolio

• Evolus highlighted a broader aesthetics portfolio built around Jeuveau neurotoxin, Evolysse hyaluronic acid fillers, and Profhilo skin-quality injections.
• Evolysse Form and Smooth showed non-inferiority at 6 months versus Restylane-L in a US pivotal nasolabial fold study of 140 patients.
• The primary endpoint analysis also showed statistical superiority at 6 months, with 95% CI [-0.5, -0.032] for Form, [-0.416, -0.019] for Smooth.
• Safety in the pivotal study was described as similar to control, with 0 serious adverse events and 0 delayed-onset nodules for both products.
• Profhilo was positioned as a European market-leading skin-quality injectable, cited as 4.8 million treatments across 70+ countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.